证券之星消息，截至2025年12月15日收盘，美好医疗(301363)报收于21.06元，上涨1.01%，换手率 1.26%，成交量4.72万手，成交额1.0亿元。 12月15日的资金流向数据方面，主力资金净流出346.11万元，占总成交额3.45%，游资资金净流入 271.51万元，占总成交额2.7%，散户资金净流入74.6万元，占总成交额0.74%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净流入 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-12-15 | 21.06 | 1.01% | -346.11万 | -3.45% | 271.51万 | 2.70% | 74.60万 | - 0.74% | | 2025-12-12 | 20.85 -0.48% | | -630.04万 | -6.93% | 158.75万 | 1.75% | 471.29万 | 5.18% | | 2025-12-11 | 20.95 | 2.2 ...

证券之星消息，截至2025年12月12日收盘，美好医疗(301363)报收于20.85元，下跌0.48%，换手率 1.16%，成交量4.32万手，成交额9091.33万元。 12月12日的资金流向数据方面，主力资金净流出630.04万元，占总成交额6.93%，游资资金净流入 158.75万元，占总成交额1.75%，散户资金净流入471.29万元，占总成交额5.18%。 该股最近90天内共有12家机构给出评级，买入评级10家，增持评级2家；过去90天内机构目标均价为 25.32。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资金流 向。 注：主力资金为特大单成交，游资为大单成交，散户为中小单成交 近5日资金流向一览见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备3101043457 ...

该股主要指标及行业内排名如下： 证券之星消息，截至2025年12月11日收盘，美好医疗(301363)报收于20.95元，上涨2.2%，换手率 1.56%，成交量5.82万手，成交额1.22亿元。 12月11日的资金流向数据方面，主力资金净流入1507.1万元，占总成交额12.35%，游资资金净流出 679.95万元，占总成交额5.57%，散户资金净流出827.15万元，占总成交额6.78%。 近5日资金流向一览见下表： 美好医疗融资融券信息显示，融资方面，当日融资买入1525.75万元，融资偿还1188.76万元，融资净买 入336.99万元。融券方面，融券卖出2500.0股，融券偿还1100.0股，融券余量3.22万股，融券余额67.42 万元。融资融券余额1.39亿元。 近5日融资融券数据一览见下表： 美好医疗2025年三季报显示，前三季度公司主营收入11.94亿元，同比上升3.28%；归母净利润2.08亿 元，同比下降19.25%；扣非净利润2.03亿元，同比下降17.85%；其中2025年第三季度，公司单季度主营 收入4.62亿元，同比上升2.56%；单季度归母净利润9390.02万元，同比上升5. ...

该股主要指标及行业内排名如下： 美好医疗2025年三季报显示，前三季度公司主营收入11.94亿元，同比上升3.28%；归母净利润2.08亿 元，同比下降19.25%；扣非净利润2.03亿元，同比下降17.85%；其中2025年第三季度，公司单季度主营 收入4.62亿元，同比上升2.56%；单季度归母净利润9390.02万元，同比上升5.89%；单季度扣非净利润 9270.68万元，同比上升9.56%；负债率11.43%，投资收益490.31万元，财务费用-2739.1万元，毛利率 39.34%。美好医疗（301363）主营业务：为全球医疗器械企业提供从产品设计开发到批量生产交付的 全流程一站式服务。 证券之星消息，截至2025年12月10日收盘，美好医疗(301363)报收于20.5元，上涨0.2%，换手率 1.06%，成交量3.96万手，成交额8104.59万元。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的 ...

证券之星消息，截至2025年12月4日收盘，美好医疗(301363)报收于21.52元，上涨1.03%，换手率 1.68%，成交量6.27万手，成交额1.34亿元。 12月4日的资金流向数据方面，主力资金净流入531.81万元，占总成交额3.98%，游资资金净流出457.73 万元，占总成交额3.43%，散户资金净流出74.08万元，占总成交额0.55%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-12-04 | 21.52 | 1.03% | 531.81万 | 3.98% | -457.73万 | -3.43% | -74.08万 | -0.55% | | 2025-12-03 | | 21.30 0.42% | 2118.31万 | 13.39% | 1423.55万 | 9.00% | -3541.86万 | -22.38% | | 2025-12-02 | | 21.2 ...

Core Viewpoint - The stock of Meihai Medical (301363) has shown a slight decline in price, with significant net outflows from major funds, indicating potential investor concerns about the company's performance and market conditions [1][2]. Group 1: Stock Performance - As of November 26, 2025, Meihai Medical's stock closed at 20.89 yuan, down 0.29% with a turnover rate of 0.78% and a trading volume of 29,300 hands, resulting in a transaction amount of 61.61 million yuan [1]. - Over the past five days, the stock has experienced fluctuations, with a notable drop on November 21, 2025, where it fell by 3.79% [2]. Group 2: Fund Flow Analysis - On November 26, 2025, the net outflow of major funds was 479.83 million yuan, accounting for 7.79% of the total transaction amount, while retail investors saw a net inflow of 106.12 million yuan, representing 1.72% of the total [1][2]. - The recent trend shows that major funds have been withdrawing, with a cumulative net outflow over the past five days [2]. Group 3: Financial Metrics and Industry Comparison - Meihai Medical's total market capitalization is 11.884 billion yuan, with a net asset value of 3.702 billion yuan and a net profit of 208 million yuan [3]. - The company's price-to-earnings ratio (P/E) stands at 42.81, which is lower than the industry average of 54.59, while its price-to-book ratio (P/B) is 3.21, also below the industry average of 3.86 [3]. - The gross margin for Meihai Medical is 39.34%, significantly lower than the industry average of 51.22%, indicating potential challenges in cost management [3]. Group 4: Recent Institutional Ratings - In the last 90 days, 14 institutions have rated Meihai Medical, with 12 buy ratings and 2 hold ratings, suggesting a generally positive outlook among analysts [4]. - The average target price set by institutions over the past 90 days is 25.2 yuan, indicating potential upside from the current trading price [4].

Core Insights - The stock of Meihao Medical (301363) closed at 20.95 yuan on November 25, 2025, with a slight increase of 0.58% and a trading volume of 34,400 hands, resulting in a transaction amount of 72.4574 million yuan [1] Fund Flow Analysis - On November 25, 2025, the net outflow of main funds was 2.3287 million yuan, accounting for 3.21% of the total transaction amount, while retail investors saw a net inflow of 465,400 yuan, representing 0.64% of the total [1][2] - Over the past five days, the stock experienced fluctuating fund flows, with significant net outflows from main funds on November 24 and November 21, totaling 4.2916 million yuan and 5.3390 million yuan respectively [2] Company Performance Metrics - Meihao Medical's total market capitalization is 11.918 billion yuan, with a net asset value of 3.702 billion yuan and a net profit of 208 million yuan [3] - The company's price-to-earnings ratio (P/E) stands at 42.93, while the price-to-book ratio (P/B) is 3.22, indicating a relatively high valuation compared to the industry averages [3] - The gross margin is reported at 39.34%, which is lower than the industry average of 51.22%, while the net profit margin is 17.43%, significantly higher than the industry average of 9.57% [3] Recent Institutional Ratings - In the last 90 days, 14 institutions have rated the stock, with 12 buy ratings and 2 hold ratings, indicating a positive outlook from analysts [4] - The average target price set by institutions over the past 90 days is 25.2 yuan, suggesting potential upside from the current trading price [4]

Core Viewpoint - The stock of Meihao Medical (301363) has shown a slight increase in price, with significant net inflows from major funds, indicating potential investor interest despite some outflows from retail investors [1][2]. Financial Performance - As of November 20, 2025, Meihao Medical's stock closed at 21.12 yuan, up 0.62%, with a trading volume of 30,300 lots and a total transaction value of 63.8864 million yuan [1]. - In the third quarter of 2025, the company reported a main business revenue of 462 million yuan, a year-on-year increase of 2.56%, and a net profit attributable to shareholders of 93.9002 million yuan, a year-on-year increase of 5.89% [3]. - For the first three quarters of 2025, the company's main revenue was 1.194 billion yuan, a year-on-year increase of 3.28%, while the net profit decreased by 19.25% to 208 million yuan [3]. Market Position and Valuation - Meihao Medical's total market capitalization is 12.015 billion yuan, with a net asset value of 3.702 billion yuan and a net profit of 208 million yuan [3]. - The company's price-to-earnings ratio (P/E) is 43.28, which is lower than the industry average of 55.37, indicating a relatively favorable valuation [3]. - The gross profit margin stands at 39.34%, significantly lower than the industry average of 51.22%, while the net profit margin is 17.43%, higher than the industry average of 9.57% [3]. Institutional Ratings - Over the past 90 days, 14 institutions have rated the stock, with 12 buy ratings and 2 hold ratings, suggesting a positive outlook from analysts [4]. - The average target price set by institutions for the stock is 25.2 yuan, indicating potential upside from the current trading price [4].

Core Insights - The stock of Meihao Medical (301363) closed at 23.51 yuan on October 31, 2025, with a rise of 2.71% and a trading volume of 59,900 hands, amounting to a total transaction value of 141 million yuan [1] Financial Performance - For the first three quarters of 2025, Meihao Medical reported a main business revenue of 1.194 billion yuan, an increase of 3.28% year-on-year, while the net profit attributable to shareholders was 208 million yuan, a decrease of 19.25% year-on-year [3] - In Q3 2025, the company achieved a single-quarter main business revenue of 462 million yuan, up 2.56% year-on-year, and a net profit attributable to shareholders of 93.90 million yuan, an increase of 5.89% year-on-year [3] - The company's gross profit margin stands at 39.34% [3] Market Position - Meihao Medical's total market capitalization is 13.374 billion yuan, which is higher than the industry average of 11.561 billion yuan, ranking 23rd out of 124 in the medical device industry [3] - The company's price-to-earnings ratio (P/E) is 48.18, which is lower than the industry average of 62.61, ranking 53rd out of 124 [3] - The net profit margin of Meihao Medical is 17.43%, significantly higher than the industry average of 9.57%, ranking 42nd out of 124 [3] Investment Sentiment - In the last 90 days, 17 institutions have rated the stock, with 15 buy ratings and 2 hold ratings, and the average target price set by institutions is 25.2 yuan [4]

Core Viewpoint - The stock of Meihao Medical (301363) has experienced a decline of 2.8% as of October 30, 2025, with significant net outflows from major funds, indicating potential concerns among institutional investors [1][2]. Financial Performance - For the first three quarters of 2025, Meihao Medical reported a main revenue of 1.194 billion yuan, a year-on-year increase of 3.28%, while the net profit attributable to shareholders was 208 million yuan, a decrease of 19.25% [3]. - In Q3 2025, the company achieved a single-quarter main revenue of 462 million yuan, up 2.56% year-on-year, and a net profit of 93.9 million yuan, an increase of 5.89% [3]. - The company's gross margin stands at 39.34%, with a net profit margin of 17.43% [3]. Market Position - Meihao Medical's total market capitalization is 13.021 billion yuan, ranking 23rd in the medical device industry, while its net assets are 3.702 billion yuan, ranking 41st [3]. - The company has a price-to-earnings ratio (P/E) of 46.91, which is lower than the industry average of 60.08, ranking 53rd [3]. - The return on equity (ROE) is 5.79%, significantly higher than the industry average of 0.15%, ranking 43rd [3]. Fund Flow Analysis - On October 30, 2025, the net outflow of major funds was 8.9506 million yuan, accounting for 9.41% of the total transaction amount, while retail investors saw a net inflow of 8.6334 million yuan, representing 9.08% [1][2]. - Over the past five days, the stock has seen fluctuating fund flows, with significant net outflows from major funds on multiple days [2]. Analyst Ratings - In the last 90 days, 17 institutions have rated the stock, with 15 buy ratings and 2 hold ratings, indicating a generally positive outlook among analysts [4]. - The average target price set by institutions over the past 90 days is 25.2 yuan [4].